Infantile Neuroaxonal Dystrophy  - Market Insights, Epidemiology and Market Forecast 2028

Infantile Neuroaxonal Dystrophy - Market Insights, Epidemiology and Market Forecast 2028

  • Pages: 120
  • Geography: Global
  • Delivery Timeline: 5 Business Days
  • Publication: Aug, 2019
  • SKU: DIMI0353
  • Single User License
    (20% Off)
    $6,250.00
  • Site License
    (30% Off)
    $12,500.00
  • Global License
    (40% Off)
    $18,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight’s ‘Infantile Neuroaxonal Dystrophy  - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Infantile Neuroaxonal Dystrophy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Infantile Neuroaxonal Dystrophy from 2016 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2016-2028
Infantile Neuroaxonal Dystrophy - Disease Understanding and Treatment Algorithm
Infantile Neuroaxonal Dystrophy (INAD) or PLA2G6-Associated Neurodegeneration (PLAN), which is also known as, Neurodegeneration with Brain Iron Accumulation (NBIA) and Seitelberger Disease, is an ultra-rare, devastating life-shortening neurodegenerative disorder that affects only a few hundred patients worldwide. It is caused by a genetic defect in the PLA2G6 housekeeping gene that removes damaged lipids from cells. Many children with INAD do not live beyond age 10, but some do survive into their teens or later ages.
The DelveInsight Infantile Neuroaxonal Dystrophy market report gives the thorough understanding of the Infantile Neuroaxonal Dystrophy by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Infantile Neuroaxonal Dystrophy in the US, Europe, and Japan.

Infantile Neuroaxonal Dystrophy Epidemiology
The Infantile Neuroaxonal Dystrophy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Infantile Neuroaxonal Dystrophy in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2028.
As per National Institutes of Health (USA), infantile neuroaxonal dystrophy is a very rare disorder. Its specific incidence is unknown. According to Great Ormond Street Hospital for Children NHS Foundation Trust, each pregnancy carries a 25 percent chance of the child being affected.

Infantile Neuroaxonal Dystrophy Drug Chapters
This segment of the Infantile Neuroaxonal Dystrophy report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Although there is no treatment yet available that can stop the disease, drugs are be given to treat infections, pain relief and sedative drugs can be given if required, and feeding can be assisted. Oral or intrathecal baclofen can be given to those with atypical Infantile Neuroaxonal Dystrophy who have significant dystonia. Transdermal scopolamine patch can be given to reduce the volume of secretions in those with excessive drooling or difficulty controlling secretions. Because some individuals with PLA2G6-Associated Neurodegeneration (PLAN) have high brain iron and this disorder falls into the category of NBIA, the option of therapies to remove iron (chelation) is sometimes raised.

Infantile Neuroaxonal Dystrophy Market Outlook
The Infantile Neuroaxonal Dystrophy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 
Currently, the pipeline for INAD is not so lucrative as there is only 1 drug, i.e., RT001 (Retrotope). But, the expected launch of RT001 in the future will create a positive impact on the INAD market. US FDA has granted Orphan Drug Designation for RT001 in the treatment of Phospholipase 2G6 (PLA2G6)-Associated Neurodegeneration (PLAN).

Infantile Neuroaxonal Dystrophy Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Infantile Neuroaxonal Dystrophy Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Infantile Neuroaxonal Dystrophy Report Key Strengths

• 10 Years Forecast

• 7MM Coverage 

• Epidemiology Segmentation

• Sub-type Segmentation

• Key Cross Competition 

• Highly Analyzed Market

• Drugs Uptake

Infantile Neuroaxonal Dystrophy Report Assessment

• Current Treatment Practices

• Unmet Needs

• Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Infantile Neuroaxonal Dystrophy market

• Organize sales and marketing efforts by identifying the best opportunities for Infantile Neuroaxonal Dystrophy market

• To understand the future market competition in the Infantile Neuroaxonal Dystrophy market.

1. Key Insights
2. INAD: Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Infantile Neuroaxonal Dystrophy (INAD) in 2016
2.2. Total Market Share (%) Distribution of INAD in 2028
3. Disease Background and Overview: INAD
3.1. Introduction
3.2. Signs and Symptoms
3.3. Classification of INAD
3.4. Stages and GRADE
3.5. Pathophysiology
3.6. Genetic Basis of INAD according to Genome-Wide Association Study
3.7. Causes and Risk factors for INAD
3.8. Risk Factors
3.9. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
5. 7MM Total Prevalent Patient Population of INAD
6. Country Wise-Epidemiology of INAD Disease
6.1. United States
6.1.1. Assumptions and Rationale
6.1.2. Total Prevalent Population of INAD in the United States
6.1.3. Diagnosed and Treatable cases of INAD in the United States
6.2. EU5 Countries
6.2.1. Assumptions and Rationale
6.2.2. Total Prevalent Population of INAD in the EU5 Countries
6.2.3. Diagnosed and Treatable cases of INAD in the EU5 Countries
6.3. Germany
6.3.1. Total Prevalent Population of INAD in the Germany
6.3.2. Diagnosed and Treatable cases of INAD in the Germany
6.4. France
6.4.1. Total Prevalent Population of INAD in the France
6.4.2. Diagnosed and Treatable cases of INAD in the France
6.5. Italy
6.5.1. Total Prevalent Population of INAD in the Italy
6.5.2. Diagnosed and Treatable cases of INAD in the Italy
6.6. Spain
6.6.1. Total Prevalent Population of INAD in the Spain
6.6.2. Diagnosed and Treatable cases of INAD in the Spain
6.7. United Kingdom
6.7.1. Assumptions and Rationale
6.7.2. Total Prevalent Population of INAD in the United Kingdom
6.7.3. Diagnosed and Treatable cases of INAD in the United Kingdom
6.8. Japan
6.8.1. Assumptions and Rationale
6.8.2. Total Prevalent Population of INAD in Japan
6.8.3. Diagnosed and Treatable cases of INAD in the Japan
7. Treatment Algorithm, Current Treatment, and Medical Practices
8. Unmet Needs
9. Emerging Drugs
9.1. Key Cross Competition
9.2. RT001: Retrotope
9.2.1. Product Description
9.2.2. Other Developmental Activities
9.2.3. Clinical Development
9.2.4. Safety and Efficacy
9.2.5. Advantages and Disadvantages
9.2.6. Product Profile
Drug list continued..
10. INAD: 7 Major Market Analysis
10.1. Key Findings
10.2. Market Size of INAD in 7MM
11. The United States Market Outlook
11.1.1. Total Market size of INAD
11.1.2. United States Market Size by Therapy
12. EU-5 Countries: Market Outlook
12.1. Germany
12.1.1. Total Market size of INAD
12.1.2. Germany Market Size by Therapy
12.2. France
12.2.1. Total Market size of INAD
12.2.2. France Market Size by Therapy
12.3. Italy
12.3.1. Total Market size of INAD
12.3.2. Italy Market Size by Therapy
12.4. Spain
12.4.1. Total Market size of INAD
12.4.2. Spain Market Size by Therapy
12.5. United Kingdom
12.5.1. Total Market size of INAD
12.5.2. United Kingdom Market Size by Therapy
13. Japan: Market Outlook
13.1. Total Market size of INAD
13.2. Japan Market Size by Therapy
14. Market Drivers
15. Market Barriers
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Table 1: Total Prevalent Population of INAD in the 7MM (2016-2028)
Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Table 3: Total Prevalent Population of INAD in the United States (2016-2028)
Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2028)
Table 8: Total Prevalent Population of INAD in Germany (2016-2028)
Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2028)
Table 13: Total Prevalent Population of INAD in France (2016-2028)
Table 15: Diagnosed and Treatable cases of INAD in France (2016-2028)
Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2028)
Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Table 23: Total Prevalent Population of INAD in Spain (2016-2028)
Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Table 28: Total Prevalent Population of INAD in the UK (2016-2028)
Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Table 33: Total Prevalent Population of INAD in Japan (2016-2028)
Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Table 38: Management of INAD
Table 40: Key recommendations for INAD
Table 43: Emerging Drugs  Analysis (Phase II / III)
Table 54: 7 Major Market Size of INAD in USD Million (2016-2028)
Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2028)
Table 56: Market Size of INAD in United States in USD Million (2016-2028)
Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Table 57: Market Size of INAD in Germany, in USD Million (2016-2028)
Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Table 58: Market Size of INAD in France, in USD Million (2016-2028)
Table 55: France Market Size of INAD by Therapy in USD Million (2016-2028)
Table 59: Market Size of INAD in the Italy, in USD Million (2016-2028)
Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2028)

 

Figure 1: Signs and Symptoms of INAD
Figure 2: Clinical manifestations of INAD
Figure 3: Different forms of INAD
Figure 4: Proposed adaptive pathophysiological pathways in INAD
Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics
Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD
Figure 7: Primary pathogenic targets in INAD with their respective treatment options
Figure 8: Representation of proposed mechanisms for INAD
Figure 9: Differential diagnosis of INAD
Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2028)
Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2028)
Figure 12: Total Prevalent Population of INAD in the United States (2016-2028)
Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2028)
Figure 14: Total Prevalent Population of INAD in Germany (2016-2028)
Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2028)
Figure 25: Total Prevalent Population of INAD in France (2016-2028)
Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2028)
Figure 30: Total Prevalent Population of INAD in Italy (2016-2028)
Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2028)
Figure 35: Total Prevalent Population of INAD in Spain (2016-2028)
Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2028)
Figure 40: Total Prevalent Population of INAD in the UK (2016-2028)
Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2028)
Figure 45: Total Prevalent Population of INAD in Japan (2016-2028)
Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2028)
Figure 50: Proposed algorithm for treatment of INAD.
Figure 51: Unmet Needs of INAD
Figure 52: 7 Major Market Size of INAD in USD Million (2016-2028)
Figure 53: Market Size of INAD in the United States, USD Millions (2016-2028)
Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 55: Market Size of INAD in Germany, USD Millions (2016-2028)
Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 57: Market Size of INAD in France, USD Millions (2016-2028)
Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2028)
Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2028)
Figure 61: Market Size of INAD in Spain, USD Millions (2016-2028)
Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2028)

 

Key Companies
Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Copyright © 2018 Delveinsight.